SFJ Pharmaceuticals
SFJ Pharmaceuticals is a Pleasanton, CA-based private drug development company that provides 100% at-risk funding and clinical development services to pharma and biotech partners in exchange for success-based milestone payments, with 17 major market approvals across 11 partnerships.
- Company typePrivate
- Founded2009
- HeadquartersPleasanton, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What SFJ Pharmaceuticals does
SFJ Pharmaceuticals is a privately held, Pleasanton, California-based pharmaceutical development company founded in 2009 by Robert DeBenedetto that pioneered a risk-sharing co-development business model. Rather than developing proprietary drugs, SFJ partners with pharmaceutical and biotech companies to provide 100% of late-stage (Phase 2/3) clinical development funding in exchange for success-based payments tied to regulatory approvals and commercial milestones. Partners retain full commercial rights to their assets, while SFJ assumes the development and approval risk, effectively offering non-dilutive capital alongside clinical and regulatory execution capabilities.
SFJ's service offering combines capital, expertise, and operational resources: it funds 100% of trial costs (avoiding partner equity dilution), designs and executes global clinical trials across the US, EU, Japan, and China, manages CRO relationships, and provides regulatory submission support across multiple jurisdictions. The model enables parallel trial execution, follow-on indication acceleration, and bridge funding to ex-US value inflection points. The company is backed by Blackstone Life Sciences (>$800B AUM) and Abingworth ($2.5B life science funds) as primary investors. Over its history, SFJ has completed 11 partnerships with $4.5 billion in total committed deal value, achieved 17 major market regulatory approvals, and executed 6 oncology-specific partnerships.
Notable co-developed assets include Lenvatinib (Eisai, thyroid cancer), Mylotarg and Inotuzumab (Pfizer, leukemia), Dacomitinib/Vizimpro (Pfizer, lung cancer), EMPAVELI/pegcetacoplan (Apellis, PNH), bentracimab (PhaseBio/SERB, ticagrelor reversal), BEMPEG (Nektar, head and neck cancer), and abituzumab (Merck KGaA, colorectal cancer). Revenue is generated through upfront fees, clinical milestone payments, and royalty-style success payments upon regulatory approval. The company is led by President and CEO Barbara White, MD (appointed 2024, joined as CMO in 2021), with CFO Jonathan DeBenedetto overseeing structured financing transactions exceeding $400M. SFJ operates as a private company with 11-50 employees, distributed across US headquarters and Asia-Pacific subsidiaries (SFJ Pharma Japan K.K., SFJ Pharmaceuticals Asia Pacific PTE. LTD.).
SFJ Pharmaceuticals firmographics
Firmographics- Name
- SFJ Pharmaceuticals
- Legal name
- SFJ Pharmaceuticals, Inc.
- Website
- https://sfj-pharma.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SFJ Pharmaceuticals is a Pleasanton, CA-based private drug development company that provides 100% at-risk funding and clinical development services to pharma and biotech partners in exchange for success-based milestone payments, with 17 major market approvals across 11 partnerships.
- Ownership category
- akta.pro rank
SFJ Pharmaceuticals industry classification
Industry- Product category
- Pharmaceutical Drug Development Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
- akta.pro secondary industries
- Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Clinical Trial Financial Management & Payments (Site Budgeting) (HLAGACAM)
Keywords
Where SFJ Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Pleasanton
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
SFJ Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Risk-based development funding and milestone payments: SFJ provides 100% of clinical development funding for partner assets in exchange for success-based payments tied to regulatory approvals and commercial milestones. They assume all development and approval risk while partners retain commercial rights. Payments typically include upfront fees, clinical milestone payments, and royalty-style success payments upon approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
SFJ Pharmaceuticals product offering
Product offeringCore offering
SFJ Pharmaceuticals funds and executes late-stage (Phase 2/3) clinical development for pharmaceutical and biotechnology partners under risk-sharing co-development agreements, providing 100% of development funding and assuming full development and regulatory approval risk in exchange for upfront fees, milestone payments, and success-based payments tied to approvals. The company augments partner teams with clinical trial design, trial execution, CRO management, regulatory strategy across US/EU/Japan/China, and CMC oversight, while partners retain full commercial rights to their assets.
Product overview
SFJ Pharmaceuticals operates as a global drug development company offering a unified co-development partnership platform rather than discrete software products. The core offering combines at-risk capital funding with clinical development expertise, providing non-dilutive financing and full-service trial management to pharmaceutical and biotechnology partners. Services include trial design and execution, regulatory submission support, and global market expansion expertise. SFJ has successfully co-developed multiple partnered products including Vizimpro (dacomitinib) with Pfizer, EMPAVELI (pegcetacoplan) with Apellis, bentracimab (PB2452) with PhaseBio, and BEMPEG with Nektar, among others.
Differentiator
Problem solved
Functional benefit
Products and services
- Risk-Sharing Co-Development Partnership Program A B2B drug development partnership offering in which SFJ provides 100% of late-stage (Phase 2/3) clinical development funding and assumes full development and regulatory approval risk in exchange for upfront fees, milestone payments, and success-based payments tied to approvals; partners retain full commercial rights to their assets. Designed for pharmaceutical and biotech companies with late-stage pipeline assets and funding or operational gaps.
- Global Clinical Trial Design and Execution Services End-to-end clinical trial design and execution services delivered as part of co-development partnerships, including trial design, CRO management, global multi-country trial operations, and execution oversight across US, EU, Japan, and China. Targeted at pharmaceutical and biotech partners running Phase 2/3 registrational programs.
- Global Regulatory Submission and Strategy Services Regulatory affairs services delivered as part of co-development partnerships, including submission strategy and filings across the US FDA, EU EMA, Japan PMDA, and China NMPA, supported by SFJ's SVP/Chief Regulatory Officer. Targeted at partners needing multi-market regulatory expertise alongside funding.
- Non-Dilutive Late-Stage Development Financing Capital funding product that covers 100% of late-stage clinical trial costs for partner assets without requiring equity dilution, structured as upfront fees, clinical milestone payments, and success-based payments upon regulatory approval. Targeted at biotech and pharma partners seeking to preserve equity and avoid shareholder dilution.
- CMC and Manufacturing Supply Oversight Chemistry, Manufacturing and Controls (CMC) oversight and supply assurance services delivered as part of co-development partnerships, including strategic oversight of manufacturing and analytical testing activities to support successful supply and approval of partnered medicines. Targeted at pharmaceutical and biotech partners requiring CMC leadership alongside funding.
Quantifiable outcome
- 17 major market regulatory approvals achieved through partnerships
- +3 more outcomes
Companies that use SFJ Pharmaceuticals
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles2 records
SFJ Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
SFJ Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered major and flagship.
- SERB PharmaceuticalsmajorSERB acquired exclusive US rights to bentracimab from SFJ. SFJ retained responsibility for ongoing clinical trials and BLA submission collaboration. Bentracimab BLA accepted for FDA priority review in 2024.
- Nektar TherapeuticsmajorFinancing and co-development collaboration for Bempegaldesleukin (BEMPEG) plus pembrolizumab in head and neck cancer. SFJ committed up to $150M funding for Phase 2/3 registrational study with success-based milestone payments over 7-8 years.
- PhaseBio PharmaceuticalsflagshipFinancing and co-development collaboration for PB2452 (bentracimab), a reversal agent for ticagrelor. SFJ committed up to $120M in development funding and assumed central role in global clinical development outside US. Bentracimab received FDA Breakthrough Therapy Designation.
- Apellis PharmaceuticalsflagshipNovel risk-sharing collaboration for APL-2 (pegcetacoplan) development in hematologic indications including PNH. SFJ provided up to $250M in financing. First time SFJ partnered with a pre-revenue biotech company. Product received FDA approval as EMPAVELI in 2021.
- Merck KGaA (EMD Serono)majorRisk-sharing collaboration for abituzumab development as first-line treatment for metastatic colorectal cancer (mCRC) in combination with Erbitux and chemotherapy, targeting RAS wild-type left-sided tumors with high ανβ6 integrin expression.
- EisaiflagshipCollaborative development agreement for Lenvatinib (Lenvima). SFJ supported late-stage clinical development. Drug achieved multiple major market approvals (US, EU, Japan, China) for thyroid cancer.
- PfizerflagshipMultiple co-development partnerships including: Mylotarg (gemtuzumab ozogamicin) for AML approved 2017, Inotuzumab ozogamicin (Besponsa) for ALL approved 2017, and Dacomitinib (Vizimpro) for lung cancer approved 2018 in multiple markets.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
SFJ Pharmaceuticals competitors and assessment
Company assessmentOthers
- OrbiMed: OrbiMed is a large healthcare-dedicated investment firm that provides structured capital and company-building support to biotechs. While its core vehicles are traditional equity and credit, it competes for the same partner assets and capital allocation decisions as SFJ.
- Pappas Capital: Pappas Capital invests in and partners with life science companies across stages, providing both venture capital and partnership-style support. It is an adjacent investor rather than direct risk-sharing competitor but operates in the same partner-discovery ecosystem.
Direct peers
- Athyrium Capital Management: Athyrium deploys structured capital to healthcare and life sciences companies, including royalty-based and milestone-linked financing transactions that compete with SFJ's at-risk development funding model.
- Innovatus Capital Partners: Innovatus's life sciences vertical provides structured financing — including royalty and milestone-based facilities — to biopharma companies, placing it in SFJ's competitive set for development-stage risk-sharing deals.
- HealthCare Royalty Partners (HCR): HCR is the most direct analogue to SFJ's risk-sharing development-financing model. HCR purchases royalties and funds late-stage development in exchange for milestone/royalty streams — a transaction structure nearly identical to SFJ's co-development partnerships.
- K2 HealthVentures: K2 HealthVentures provides structured debt and royalty financing to life science companies across development stages, overlapping with SFJ's risk-bearing capital solutions for late-stage programs.
- Deerfield Management: Deerfield's structured capital arm provides non-dilutive financing and operational support to clinical-stage biotechs in exchange for milestones and royalties, directly mirroring SFJ's core offering on the capital side of the deal.
Broad incumbents
- Royalty Pharma: Royalty Pharma acquires royalty streams on approved and late-stage biopharma assets, competing for the same risk-adjusted cash flow that motivates SFJ's deals. It is a broader incumbent focused on post-approval and pre-approval royalty purchases rather than development operations.
- IQVIA: IQVIA is the largest contract research organization and has built an adjacent financial services capability that overlaps with SFJ's trial execution and financing functions, though IQVIA's primary business is service-fee CRO work rather than at-risk development financing.
- Blackstone Life Sciences: Blackstone Life Sciences (formerly Clarus) is SFJ's primary investor and operates a parallel risk-sharing development finance franchise across larger funds and a broader set of deal structures. It shares SFJ's underlying thesis but operates at materially larger scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
SFJ Pharmaceuticals social profiles
Digital presenceSFJ Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
SFJ Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles8 records
SFJ Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds6 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SFJ Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SFJ Pharmaceuticals
What does SFJ Pharmaceuticals do?
SFJ Pharmaceuticals funds and executes late-stage (Phase 2/3) clinical development for pharmaceutical and biotechnology partners under risk-sharing co-development agreements, providing 100% of development funding and assuming full development and regulatory approval risk in exchange for upfront fees, milestone payments, and success-based payments tied to approvals. The company augments partner teams with clinical trial design, trial execution, CRO management, regulatory strategy across US/EU/Japan/China, and CMC oversight, while partners retain full commercial rights to their assets.
Is SFJ Pharmaceuticals a public or private company?
SFJ Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was SFJ Pharmaceuticals founded?
SFJ Pharmaceuticals was founded in 2009. It employs 11 to 50 people.
Where is SFJ Pharmaceuticals based?
SFJ Pharmaceuticals is headquartered in Pleasanton, United States, in the North America region.
How does SFJ Pharmaceuticals make money?
One revenue line is on record: risk-based development funding and milestone payments.
Who are SFJ Pharmaceuticals's main competitors?
Others on record are OrbiMed and Pappas Capital. Direct peers are Athyrium Capital Management, Innovatus Capital Partners, HealthCare Royalty Partners (HCR), K2 HealthVentures and Deerfield Management. Broad incumbents are Royalty Pharma, IQVIA and Blackstone Life Sciences.
Does SFJ Pharmaceuticals have an API?
No public API is recorded for SFJ Pharmaceuticals.
What industry is SFJ Pharmaceuticals in?
SFJ Pharmaceuticals's product category is Pharmaceutical Drug Development Services. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAGAKAA, Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA). Its NAICS code is 5417 and its SIC code is 8731.